Kornimate/medical-research-clean huggingface dataset:
naltrexone/bupropion (mysimba) to optimize weight outcomes after obesity surgery

Conditions: Obesity

Summary: limited/poor weight loss and weight regain are concerns following bariatric surgery, and weight regain may increase the risk for relapse of comorbidities related to obesity. medications for weight reduction may assist further weight loss, and support weight maintenance, with positive effects on comorbidities. this pilot study will examine the effect of naltrexone/bupropion and lifestyle advice versus lifestyle advice alone for 7 months in patients with a suboptimal weight trajectory (either little weight loss or weight regain) 2 years or later following bariatric surgery.

study aim and endpoints the aim of this pilot study is to evaluate the effect of mysimba in patients with suboptimal weight loss or weight regain after bariatric surgery. the primary endpoint is body weight. objective the study objective is to understand whether patients with suboptimal weight loss or weight regain 2 years or more following bariatric surgery achieve better weight loss with mysimba and dietary counselling compared with a control group treated with dietary counselling alone. this is a phase iv, open label randomized controlled study conducted over 7 months with a 3-month post-intervention follow-up. the study will be conducted in accordance with good clinical practice. patients meeting eligibility criteria will be randomized into one of two groups: an intervention group treated with mysimba and lifestyle and a control group treated with lifestyle. the intervention group will be prescribed mysimba gradually titrated to the maximum tolerated dose (maximum dose is 32 mg/360 mg divided in 4 tablets) with 2 week intervals. both groups will receive the same follow up including dietary counselling during the course of the study. randomization will be done using a standard internet-based program where group assignment cannot be anticipated. the study is not blinded.

Eligibility criteria:
inclusion criteria: men and women aged 18-65 years who have undergone rygb, mini-rygb or sleeve gastrectomy 2 or more years previously and either 1. have a percent total weight loss from time of surgery of \<20% or 2. have a regain of at least 5% or more of nadir weight (lowest weight at 12-18 months after surgery) and 3. meet current clinical criteria for use of mysimba (bmi ≥30 kg/m2 or bmi ≥27 kg/m2 with obesity-related comorbidity (diabetes type 2, controlled hypertension, dyslipidemia) exclusion criteria: * serious illness or complications due to bariatric surgery according to the judgement of the investigators and clinical records * use of any weight loss medications following bariatric surgery * pregnancy or breastfeeding * participation in other weight loss studies * contraindication for use of mysimba. these include but are not limited to epilepsy or history of seizure, uncontrolled hypertension (blood pressure ≥150/95 mmhg with or without medication), previous or current eating disorder, substance abuse, bipolar depression, serious liver or kidney disease, use of certain medications)
educational program for knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: sixty patients with a diagnosis of knee osteoarthritis, aged between 40 and 80 years, of both genders were included. the patients were divided into: experimental group that carried out an educational program - 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes and the transcutaneous nerve electro-stimulation device - being performed twice weekly, for 5 weeks for 40 minutes each session; and control group who only underwent treatment with the transcutaneous nerve electro-stimulation in the same parameters as experimental group. the evaluations were performed at the beginning of the treatment, 4 and 12 weeks after the beginning of the treatment using a numerical pain scale; womac; idate and sf-36 questionnaires; and 6-minute walk test.


Eligibility criteria:
inclusion criteria: * diagnosis of knee osteoarthritis by american college of rheumatology criteria; * age between 40 and 80 years; * both genders; * numerical pain scale in the knee between 3 and 8 centimeters on a scale of 0 to 10 centimeters. exclusion criteria: * systemic inflammatory diseases or any condition that prevents the practice of physical activity; * regular physical activity started or changed in the last twelve weeks; * no ambulation; * joint injection in the knee in the previous twelve weeks; * previous knee surgery or surgery planned for the next twenty-four weeks; * physiotherapy in the last twelve weeks; * other disease that affects the lower limbs; * open wounds at the electrode application site; * planned trip in the next twelve weeks.

Keywords: education pain function quality of life
h. pylori treatment between modified quadruple regimen and tailored therapy

Conditions: H. Pylori Infection

Summary: the rate of h. pylori resistance to antimicrobial agents including clarithromycin (cam) has increased worldwide. eradication failure using triple therapy is strongly associated with cam-resistant h. pylori. the tailored therapy is defined as a targeted h. pylori eradication which emphasizes on predicting individual drug responses before treatment. dual priming oligonucleotide (dpo)-based multiplex polymerase chain reaction (pcr) was developed to diagnose h. pylori infection and identify cam resistance. the use of dpo-pcr has increased the tailored h. pylori eradication rate in korea. if dpo-pcr testing is not available, a 14-day modified bismuth-containing quadruple regimen is recommended as a first-line h. pylori eradication. however, there is no comparison study between modified quadruple therapy and tailored eradication based on the presence of cam resistance using dpo-pcr.

the investigators aim to evaluate the success rate, adverse drug events, and cost-effectiveness of modified quadruple therapy, compared with tailored eradication based on the presence of cam resistance.

Eligibility criteria:
inclusion criteria: * gastroscopy can be performed * h. pylori test and pathological analysis can be performed exclusion criteria: * age \ 80 years * anemia (serum hemoglobin level \< 10 g/dl) * severe systemic disease * advanced chronic liver disease * use of certain medications, including proton pump inhibitors, h2- receptor antagonists, or antibiotics * history of h. pylori eradication * history of gastric surgery * recent history of upper gastrointestinal bleeding
rhabdomyosarcoma and malignant soft tissue tumours of childhood

Conditions: Rhabdomyosarcoma; Malignant Soft Tissue

Summary: objective of the study objectives was to explore survival advantage for an intensified chemotherapy strategy in a randomised trial. iva (ifosfamide, vincristine, actinomycin d) or a 6 drug combination (iva + carboplatin, epirubicin, etoposide) both delivered over 27 weeks. cumulative dose / m2 = ifosfamide 54g (both arms), epirubicin 450 mg, etoposide 1350 mg (6 drug). delivery of radiotherapy was determined according to site and / or response to chemotherapy ± surgery. the study was powered to detect 10% difference in 3 year os.


Eligibility criteria:
inclusion criteria: * age \> 6 months and \< 18 years * no distant metastases * diagnosis within previous 8 weeks without prior treatment except surgery * pathology available for central review * written consent according to institutional requirement exclusion criteria: * stage iii (node positive) * stage i or ii non alveolar orbital tumours * patients with parameningeal disease aged \< 3 years
to achieve blood pressure control with retained quality of life

Conditions: Hypertension; Patient Compliance

Summary: the purpose of the study is to get an understanding about what problems patients with hypertension are facing, how they manage these challenges, how they feel and what requirements they believe are important to have in their treatment. these factors will later act as a foundation and incentive for designing an intervention that may result in more patients achieving blood pressure control with maintained quality of life.

this is a swedish observational mixed-methods study to get an understanding about what problems patients with hypertension are facing. the information will act as a foundation for designing an intervention/interventions that may result in more patients achieving blood pressure control with maintained quality of life. patients, who have well/not well controlled blood pressure, are to fill in questionnaires about their view on ability to perform self-care and their perceived quality of life. individual interviews will also be made about for what reasons they do or do not change lifestyle as well as take their drugs to treat their hypertension. in focus group interviews the patients are to be asked about what they want and expect in the encounter with health care personnel, what other things outside the health care area would be helpful for the patient and how age, gender, cultural and psychosocial aspects affect the ability to achieve blood pressure control. the developed future interventions will be evaluated in clinical practice.

Eligibility criteria:
inclusion criteria: * diagnosed with hypertension since 9 months * being able to read and speak swedish exclusion criteria: -

Keywords: hypertension blood pressure control adherence mixed methods
cranberry extract and urinary infection prevention: a clinical trial

Conditions: Urinary Tract Infections

Summary: the purpose of this clinical trial study is to assess, among young and sexually active women presenting recurrent urinary tract infection (utis), efficacy of an optimal dose of cranberry extract quantified and standardized to 37 mg/day of proanthocyanidins (pacs), compared to a control dose quantified and standardized to 2 mg/day of pacs on mean number of new utis during a 6-month follow-up period.

cranberry juice, fruit (fresh and dried), functional foods, and cranberry dietary supplements are promoted for prevention of urinary tract infections (utis) on the basis of their content of cranberry proanthocyanidins (pacs) with "a-type" interflavan bonds. several clinical trials have assessed efficacy of cranberry-derived products, essentially with cranberry juices, but discordant results have been found. lack of compliance but mostly lack of standardization in product concentrations can account for the variability among results. indeed, most clinical trials do not report quantity of pacs. according to most recent studies, quantification of pacs requiring standardized and reproducible methods should be at least 37 mg/day. it can be hypothesized that efficacy of cranberry extract in utis prevention among young women can be strongly increased using optimal dosage (standardized to 37 mg/day of pacs). the purpose of this clinical trial study is to assess, among young and sexually active women presenting recurrent utis, efficacy of an optimal dose of cranberry extract quantified and standardized to 37 mg/day of pacs, compared to a control dose quantified and standardized to 2 mg/day of pacs on mean number of new utis during a 6-month follow-up period.

Eligibility criteria:
inclusion criteria: * healthy and sexually active women * aged between 18 to 45 years old * recurrence of 2 utis in the past 6 months or 3 in the past year * do not have consumed cranberry juice, polyphenols or antioxidant supplements in the last 2 weeks * internet access exclusion criteria: * women who have personal history of acute or chronic renal failure * women who have personal history of urogenital system anomalies, urogenital tractus surgery or intestinal diseases causing malabsorption (e.g., crohn and celiac diseases) * women who have personal history of kidney stones, taking anticoagulant medication or have taken anticoagulant medication in the last month * women presenting cranberry allergy or intolerance

Keywords: cranberry proanthocyanidins urinary catabolites
thai msm/tg test and treat study

Conditions: HIV Testing Rate; Acceptance of Immediate ART

Summary: objectives 1. to determine the uptake of universal hiv testing among thai men who have sex with men (msm) and transgender women (tg) 2. to determine the uptake of antiretroviral treatment (art) regardless of cd4 count among thai msm/tg who test positive for hiv subject population:. men or transgender women who have sex with men,thai nationals, age ≥18 years old, have engaged in anal intercourse with a man without using a condom at least one time in the last 6 months or have had at least 3 male sex partners in the last 6 months,not known to be hiv-positive (either have never been tested for hiv or have had a previous negative hiv test) number of participants:2000 thai msm and tg with approximately 76%-90% in bangkok, 5%-12% in lampang and 5-12% in ubonratchathani.

all participants will receive hiv testing at baseline. the frequency of study visits to determine hiv status in hiv-negative participants will be every 6 months for a total follow up time of 24 months. once hiv-positive status is confirmed, participants will be offered art immediately regardless of cd4 count. those who accept art will be seen more frequently following art initiation, at 2 weeks, 4 weeks, 2 months, 3 months and every 3 months thereafter until completion of 24 months of follow-up. those who deny immediate art will have clinic visits every 6 months to monitor hiv disease. hiv-negative participants will be asked to come for hiv re-testing every 6 months or sooner if they feel exposed to risk

Eligibility criteria:
inclusion criteria: 1. thai nationals 2. age \>18 years 3. men or transgender women who have sex with men 4. have engaged in anal intercourse with a man without using a condom at least one time in the last 6 months or have had at least 3 male sex partners in the last 6 months 5. not known to be hiv-positive (either have never been tested for hiv or have had a previous negative hiv test) 6. have signed the consent form exclusion criteria: 1. known hiv-positive serostatus

Keywords: 2000 msm and tg sites in bangkok,lampang,ubonratchathani
evaluation of cyclaplex implant for correction of first inter metatarsal angle in subjects suffering from hallux valgus deformity

Conditions: Hallux Valgus

Summary: the purpose of the study is to evaluate safety, tolerability and performance of the cyclaplex implant, a button and suture type implant device and instruments for the correction of the first inter metatarsal angle in subjects suffering from hallux valgus deformity.


Eligibility criteria:
inclusion criteria: * weight less than 100 kilos * ima greater than 12 degrees * ima less than 7 degrees exclusion criteria: * diabetics * known osteoporosis * known allergy or hypersensitivity to metals * gout or any systemic inflammatory arthropathy
heartfulness meditation and corporate burnout

Conditions: Burnout; Meditation; Stress; Heartfulness

Summary: the purpose of this study is to evaluate the effect of a 4-week heart-based meditation practice wellness workshop on burnout and emotional wellness in corporate employees. corporate employees can be defined as individuals who work in large institutions with greater than 300 employees. the specific aim of this study is to assess changes in scores measuring symptoms of emotional exhaustion, depersonalization, and personal accomplishment using the maslach burnout index. we hypothesize that the meditation wellness practice will be associated with reduction in burnout for those who take part in the meditation program in comparison to the participants who did not meditate and participate in the wellness program.


Eligibility criteria:
inclusion criteria: * adults above 18 years of age willing to participate in the study. exclusion criteria: * individuals less than 18 years of age, active suicidal ideation, current or past diagnoses of serious psychotic disorders- schizophrenia, personality disorders and post-traumatic stress disorder.
an open-label study of n-acetyl cysteine in children with autism

Conditions: Autistic Disorder

Summary: the purpose of the study is to test the tolerability and efficacy of n-acetyl cysteine (nac) in children with autism.

n-acetyl cysteine (nac) is a compound that increases the levels of glutathione, the body's main antioxidant. glutathione is a compound in the blood that is part of a natural defense system (the antioxidant system). anti-oxidants protect the body from damage caused by internal toxins called free radicals. it is possible that children with autism tend to have lower levels of glutathione, an important compound in our bodies that helps combat the effects of toxic free radicals. we hope that by studying the antioxidant system in more detail, we will increase our understanding of the reasons why people develop autism so that we can design better ways to treat individuals with this condition. this study is meant to test the safety tolerability of n-acetyl cysteine and its effectiveness in the treatment of behavioral difficulties in children with autism. it will also examine the possible benefit of this agent in improving the core deficits in autism such as social deficits.

Eligibility criteria:
inclusion criteria: subjects will be eligible for this study if they participated in the double-blind, randomized, placebo controlled study of n-acetyl cysteine in autism study at stanford university and meet all of the following criteria: 1. outpatients between 3.0 and 12.11 years of age inclusive 2. males and females who are physically healthy 3. diagnosis of autism based on diagnostic and statistical manual (dsm-iv-tr) criteria, the autism diagnostic interview-revised, and expert clinical evaluation 4. clinical global impression severity rating of 4 5. care provider who can reliably bring subject to clinic visits, can provide trustworthy ratings, and interacts with subject on a regular basis 6. ability of subject to swallow the compound 7. stable concomitant medications for at least 2 weeks 8. no planned changes in psychosocial interventions during the open-label n-acetyl cysteine trial exclusion criteria: 1. diagnostic and statistical manual (dsm-iv-tr) diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder, not otherwise specified 2. active medical problems: unstable seizures, significant physical illness (e.g., serious liver or renal pathology) 3. pregnancy or sexually active females 4. subjects taking antioxidant agents and glutathione prodrugs will be excluded from the study except if they have been off these compounds for at least 4 weeks

Keywords: n-acetyl cysteine
frontier registry ii bifurcation stent system registry

Conditions: Coronary Artery Disease

Summary: to assess the procedural success, performance, 30-day and 6 month clinical outcome of bifurcation stenting, and the six month incidence of clinically indicated target lesion revascularization with the use of the abbott vascular multi-link frontier coronary bifurcation stent system in patients with de novo or restenotic bifurcation lesions.

the purpose of this study is to assess the performance of the abbott vascular multi-link frontier coronary bifurcation stent system (cbss) with one and six months clinical outcomes, when used for bifurcation de novo or restenotic lesion treatment. the device allows for a stent to be implanted in the main branch and simultaneous preservation and access of the side branch for balloon dilatation or stenting when indicated.

Eligibility criteria:
inclusion criteria: * other lesions in different epicardial vessels must be successfully treated prior to bifurcation procedure. * native parent vessel suitable to receive at least a 2.5mm x 18mm frontier stent (\>2.5mm and \ 2.0mm) with a lesion length \<15mm determined by visual assessment . * target main branch vessel must be a major epicardial native vessel. * appropriate lesion morphology. * target lesion is restenosis following original treatment by ptca only (no in-stent restenosis). exclusion criteria: * estimated artery reference diameter \<2.5mm * patients with diffuse disease defined as long segments of abnormal vessel without interposed areas of normal vessel * target lesion contains thrombus. * target lesion is aorto-ostial or left main stem location. * untreated lesion \>50% diameter stenosis proximal or distal to target lesion after the planned target lesion intervention. * patients with a contraindication for anti-platelet / anti-coagulation therapy. * target lesion distal to previously placed stents. * fibrotic or calcified lesions that cannot be pre-dilated.
therapeutic ultrasound in the treatment of migraine

Conditions: Migraine; Ultrasound

Summary: headache affects the daily quality of life of patients. it has been reported that headaches may be associated with neck muscles, neck movements and trigger points in the neck drug and non-drug treatments can be used today in the treatment of headaches. various physical therapies are applied to cranial and cervical regions in non-drug therapies. therapeutic ultrasound, transcutaneous electrical nerve stimulation (tens), hotpack and manipulation are some of them.this is a randomised placebo- controlled trial to determine the efficacy of the therapeutic ultrasound in the treatment of migraine.

evidence from controlled studies suggests that non-invasive physical therapies may help prevent headaches. therapeutic ultrasound studies have generally been used in combination with other physical therapies. therapeutic ultrasound is known to act in two different ways, thermal and non-thermal. with thermal effect, it is possible to reduce pain and joint joints and increase local blood flow, while stimulating tissue regeneration, soft tissue repair, blood flow regulation in chronic ischemic tissues and protein synthesis with nonthermal effect. in addition, its effect on inflammation accelerated repair by affecting cell activities, altering platelet membrane permeability, leading to the release of serotonin and accelerating wound healing. the aim of this study is to determine whether therapeutic ultrasound is superior to placebo ultrasound in the treatment of migraine.

Eligibility criteria:
inclusion criteria: * patients between 20-65 years * patients diagnosed with migraine according to the international headache society (ihs) criteria exclusion criteria: * patients with bleeding disorders, * patients with mental disorders, * patients with malignancy, * patients with uncontrolled hypertension, * patients with uncontrolled diabetes mellitus, * patients with infection, * patients who underwent surgery in the posterior cranial region and cervical vertebra.

Keywords: migraine, therapeutic ultrasound, pain, disability